Patient-Based Therapeutics
AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas
![](http://shareandcaretowin.com/application/files/2716/7239/3712/Asset_9.png)
![](http://shareandcaretowin.com/application/files/9816/7239/3738/Asset_8.png)
![](http://shareandcaretowin.com/application/files/5916/7285/9077/Asset_10.png)
Latest News
AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.
AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang, presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024
AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial